June 14, 2021

A Comparison of SARS-CoV-2 Nucleocapsid and Spike Antibody Detection Using Three Commercially Available Automated Immunoassays

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): antibodies, testing

• A study comparing the Abbott SARS-CoV-2 nucleocapsid IgG, Beckman-Coulter SARS-CoV-2 spike IgG, and Roche Anti-SARS-CoV-2 nucleocapsid total antibody assays found that all three demonstrated 100% specificity, and sensitivities of 98%, 93%, and 90%, respectively. After the exclusion of samples from immunocompromised patients, all assays exhibited ≥95% sensitivity. In sequential samples collected from the same individuals, the Roche nucleocapsid antibody assay showed continually increasing signal intensity, with maximal values observed at the last time point examined, while the Beckman spike IgG antibody signal peaked between 14-28 days post-positive SARS-CoV-2 PCR test and steadily declined in subsequent samples.

Poore et al. (June 2021). A Comparison of SARS-CoV-2 Nucleocapsid and Spike Antibody Detection Using Three Commercially Available Automated Immunoassays. Clinical Biochemistry. https://doi.org/10.1016/j.clinbiochem.2021.05.011